Zi Yin, Chao Liu, Yajin Chen, Yu Bai, Changzhen Shang, Rongyan Yin, Dong Yin, Jie Wang – 28 January 2013 – The optimal surgical strategy for treatment of patients with synchronous colorectal liver metastases (SCLRM) remains controversial. We conducted a systematic review and meta‐analysis of all observational studies to define the safety and efficacy of simultaneous versus delayed resection of the colon and liver. A search for all major databases and relevant journals from inception to April 2012 without restriction on languages or regions was performed.

R. Scott Rector, E. Matthew Morris, Suzanne Ridenhour, Grace M. Meers, Fong‐Fu Hsu, John Turk, Jamal A. Ibdah – 28 January 2013 – Earlier reports suggest a link between mitochondrial dysfunction and development of hepatic insulin resistance. Here we used a murine model heterozygous (HET) for a mitochondrial trifunctional protein (MTP) gene defect to determine if a primary defect in mitochondrial long‐chain fatty acid oxidation disrupts hepatic insulin action.

Monika Ferlitsch, Markus Peck‐Radosavljevic, Arnulf Ferlitsch – 28 January 2013

Jing Hieng Ngu, Richard Blair Gearry, Chris Miles Frampton, Catherine A.M. Stedman – 28 January 2013 – Autoimmune hepatitis (AIH) can lead to cirrhosis, hepatic failure, and death. We aimed to identify predictors of advanced liver fibrosis at presentation, predictors of incomplete response to initial immunosuppression, and predictors of poor liver‐related outcomes in the population‐based AIH cohort from Canterbury, New Zealand. Cases diagnosed after 1980 that fulfilled standard diagnostic criteria were included.

Jessica A. Davila, Jennifer R. Kramer, Zhigang Duan, Peter A. Richardson, Gia L. Tyson, Yvonne H. Sada, Fasiha Kanwal, Hashem B. El‐Serag – 28 January 2013 – The delivery of treatment for hepatocellular carcinoma (HCC) could be influenced by the place of HCC diagnosis (hospitalization versus outpatient), subspecialty referral following diagnosis, as well as physician and facility factors. We conducted a study to examine the effect of patient and nonpatient factors on the place of HCC diagnosis, referral, and treatment in Veterans Administration (VA) hospitals in the United States.

Charalambos G. Antoniades, Julia Wendon – 28 January 2013

Manisha Balwani, Catherine Breen, Gregory M. Enns, Patrick B. Deegan, Tomas Honzík, Simon Jones, John P. Kane, Vera Malinova, Reena Sharma, Eveline O. Stock, Vassili Valayannopoulos, J. Edmond Wraith, Jennifer Burg, Stephen Eckert, Eugene Schneider, Anthony G. Quinn – 24 January 2013 – Cholesteryl ester storage disease (CESD), an inherited deficiency of lysosomal acid lipase (LAL), is an underappreciated cause of progressive liver disease with no approved therapy. Presenting features include dyslipidemia, elevated transaminases, and hepatomegaly.

Jing Wu, Chunjiong Wang, Shuo Li, Sha Li, Wanyi Wang, Jing Li, Yujing Chi, Hang Yang, Xiaomu Kong, Yunfeng Zhou, Chengyan Dong, Fan Wang, Guoheng Xu, Jichun Yang, Jan‐Åke Gustafsson, Youfei Guan – 24 January 2013 – The protein, thyroid hormone‐responsive SPOT 14 homolog (Thrsp), has been reported to be a lipogenic gene in cultured hepatocytes, implicating an important role of Thrsp in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).

Juan Chen, Anthony W.H. Chan, Ka‐Fai To, Weixian Chen, Zhenzhen Zhang, Jihua Ren, Chunli Song, Yue‐Sun Cheung, Paul B.S. Lai, Suk‐Hang Cheng, Margaret H.L. Ng, Ailong Huang, Ben C.B. Ko – 24 January 2013 – Sirtuin 1 (SIRT1) has been implicated in telomere maintenance and the growth of hepatocellular carcinoma (HCC). Nevertheless, the role of other sirtuins in the pathogenesis of HCC remains elusive. We found that sirtuin 2 (SIRT2), another member of the sirtuin family, also contributes to cell motility and invasiveness of HCC.

Thibaut Vausselin, Noémie Calland, Sandrine Belouzard, Véronique Descamps, Florian Douam, François Helle, Catherine François, Dimitri Lavillette, Gilles Duverlie, Ahmed Wahid, Lucie Fénéant, Laurence Cocquerel, Yann Guérardel, Czeslaw Wychowski, Christophe Biot, Jean Dubuisson – 24 January 2013 – Hepatitis C virus (HCV) is a major cause of chronic liver disease. Despite recent success in improving anti‐HCV therapy, additional progress is still needed to develop cheaper and interferon (IFN)‐free treatments.